40,404 Shares in Agios Pharmaceuticals, Inc. $AGIO Bought by Ieq Capital LLC

Ieq Capital LLC bought a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 40,404 shares of the biopharmaceutical company’s stock, valued at approximately $1,499,000.

Other institutional investors have also recently made changes to their positions in the company. Allworth Financial LP acquired a new stake in shares of Agios Pharmaceuticals in the second quarter valued at about $73,000. E Fund Management Co. Ltd. bought a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $291,000. BlackRock Inc. bought a new stake in Agios Pharmaceuticals in the second quarter valued at approximately $239,582,000. Deutsche Bank AG acquired a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $2,309,000. Finally, SCS Capital Management LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter valued at approximately $22,743,000.

Agios Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ AGIO opened at $33.99 on Thursday. The firm has a market cap of $2.03 billion, a PE ratio of -4.85 and a beta of 0.58. The company’s fifty day simple moving average is $35.91 and its 200 day simple moving average is $31.56. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -5.8 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Sarah Gheuens sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $30.48, for a total transaction of $914,400.00. Following the transaction, the insider directly owned 54,645 shares of the company’s stock, valued at approximately $1,665,579.60. This represents a 35.44% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AGIO. Citigroup boosted their price target on shares of Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada lifted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research note on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, June 24th. TD Cowen upgraded Agios Pharmaceuticals to a “strong-buy” rating in a report on Monday. Finally, HC Wainwright boosted their price objective on Agios Pharmaceuticals from $52.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $41.25.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.